Skip Navigation LinksGenitourinary

​​​​​​​​​​​​​Genitourinary Trials

Cancer Control/Prevention 

​Bladder and Urothelial

A031501:  Phase III randomized "Adjuvant study of MK-3475 (pembrolizumab) in muScle invaSive and locally ADvanced urOthelial caRcinoma" (AMBASSADOR) versus observation

S1605:  Phase II Trial of Atezolizumab in BCG-Unresponsive Non-Muscle Invasive Bladder Cancer

​Renal Cell, Adjuvant & High Risk

Renal Cell, Locally Advanced or Metastatic

​​​​​S1​500​:  A Randomized, Phase II Efficacy Assessment of Multiple MET Kinase Inhibitors (Cabozantinib [NSC #761968], Crizotinib [NSC #749005], Savolitinib [NSC #785348], and Sunitinib [NSC #736511]) in Metastatic Papillary Renal Carcinoma (PAPMET)​

Prostate, Adjuvant & Early Stage

​​R0924: Androgen Deprivation Therapy and High Dose Radiotherapy with or without Whole-Pelvic Radiotherapy in Unfavorable Intermediate or Favorable High Risk Prostate Cancer: A Phase III Randomized Trial

GU002: Phase II-III Trial Of Adjuvant Radiotherapy and Androgen Deprivation Following Radical Prostatectomy With or without Adjuvant Docetaxel​


Prostate, Advanced & Metastatic

​S1216 (CIRB): A Phase III Randomization Trial Comparing Androgen Deprivation Therapy + TAK-700 with Androgen Deprivation Therapy + Bicalutamide in Patients with Newly Diagnosed Metastatic Hormone Sensitive Prostate Cancer

ONC-MA-1004 (TRUMPET): A Prospective Observational Cohort STudy of Patients with Castration-Resistant Prostate Cancer (CRPC) in the United States 

AFT​-19A Phase III study of Androgen Annihilation in High-Ris​k Biochemically Relapsed Prostate Cancer​